SLRX Research and Charts

SLRX - Salarius Pharmaceuticals Inc (Healthcare: Biotechnology)

Projected Earnings Date: 0000-02-29 (Delayed quote data 2026-01-07)

Last 0.84	Change ⇑ +0.19 (+0.00%)	Volume 6,045,610
	Open 0.71	High 0.90	Low 0.69

8EMA (Daily) 0.68	40EMA (Daily) 1.16	50EMA (Daily) 1.36	STO (Daily) 31.232	MACD Hist (Daily) 0.048
8EMA (Weekly) 1.065	40EMA (Weekly) 1.85	50EMA (Weekly) 1.82	STO (Weekly) 2.397	MACD Hist (Weekly) -0.207


Company Profile
Salarius Pharmaceuticals Inc is a clinical-stage biotechnology company focused on developing effective treatments for cancers with high, unmet medical need. It is engaged in developing treatments for cancers caused by dysregulated gene expression. The company's lead epigenetic-based technology, seclidemstat (SP-2577) is a small molecule, administered orally, that inhibits the epigenetic enzyme lysine specific demethylase 1.

Disclaimer: All information provided is for informational purposes only and not intended for trading purposes or advice. The quotes and charts are not real time and have delays of at least 20 minutes. Data accuracy cannot be guaranteed as errors will occur. Please do not rely on the above information to make your stock/option trades. Neither OptionChance.com nor any of independent data providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein.